Cargando…
Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation
INTRODUCTION: The impact of coronary artery disease (CAD) on outcomes after transcatheter aortic valve implantation (TAVI) has not been clarified. Furthermore, less is known about the indication and strategy of revascularization in these high risk patients. AIMS: This study sought to determine the p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671341/ https://www.ncbi.nlm.nih.gov/pubmed/26664890 http://dx.doi.org/10.3389/fcvm.2015.00018 |
_version_ | 1782404389711904768 |
---|---|
author | Mancio, Jennifer Fontes-Carvalho, Ricardo Oliveira, Marco Caeiro, Daniel Braga, Pedro Bettencourt, Nuno Ribeiro, Vasco Gama |
author_facet | Mancio, Jennifer Fontes-Carvalho, Ricardo Oliveira, Marco Caeiro, Daniel Braga, Pedro Bettencourt, Nuno Ribeiro, Vasco Gama |
author_sort | Mancio, Jennifer |
collection | PubMed |
description | INTRODUCTION: The impact of coronary artery disease (CAD) on outcomes after transcatheter aortic valve implantation (TAVI) has not been clarified. Furthermore, less is known about the indication and strategy of revascularization in these high risk patients. AIMS: This study sought to determine the prevalence and prognostic impact of CAD in patients undergoing TAVI, and to assess the safety and feasibility of percutaneous coronary intervention (PCI) before TAVI. METHODS: Patients with severe aortic stenosis (AS) undergoing TAVI were included into a prospective single center registry from 2007 to 2012. Clinical outcomes were compared between patients with and without CAD. In some patients with CAD, it was decided to perform elective PCI before TAVI after decision by the Heart team. The primary endpoints were 30-day and 2-year all-cause mortality. RESULTS: A total of 91 consecutive patients with mean age of 79 ± 9 years (52% men) underwent TAVI with a median follow-up duration of 16 months (interquartile range of 27.6 months). CAD was present on 46 patients (51%). At 30-day, the incidences of death were similar between CAD and non-CAD patients (9 and 5%, p = 0.44), but at 2 years were 50% in CAD patients and 24% in non-CAD patients [crude hazard ratio with CAD, 2.2; 95% confidence interval (CI), 1.1–4.6; p = 0.04]. Adjusting for age, gender, left ventricular ejection fraction, and glomerular filtration rate, the hazard of death was 2.6-fold higher in patients with CAD (95% CI, 1.1–6.0; p = 0.03). Elective PCI before TAVI was performed in 13 patients (28% of CAD patients). There were no more adverse events in patients who underwent TAVI + PCI when compared with those who underwent isolated TAVI. CONCLUSION: In severe symptomatic AS who underwent TAVI, CAD is frequent and adversely impacts long-term outcomes, but not procedure outcomes. In selected patients, PCI before TAVI appears to be feasible and safe. |
format | Online Article Text |
id | pubmed-4671341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46713412015-12-10 Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation Mancio, Jennifer Fontes-Carvalho, Ricardo Oliveira, Marco Caeiro, Daniel Braga, Pedro Bettencourt, Nuno Ribeiro, Vasco Gama Front Cardiovasc Med Cardiovascular Medicine INTRODUCTION: The impact of coronary artery disease (CAD) on outcomes after transcatheter aortic valve implantation (TAVI) has not been clarified. Furthermore, less is known about the indication and strategy of revascularization in these high risk patients. AIMS: This study sought to determine the prevalence and prognostic impact of CAD in patients undergoing TAVI, and to assess the safety and feasibility of percutaneous coronary intervention (PCI) before TAVI. METHODS: Patients with severe aortic stenosis (AS) undergoing TAVI were included into a prospective single center registry from 2007 to 2012. Clinical outcomes were compared between patients with and without CAD. In some patients with CAD, it was decided to perform elective PCI before TAVI after decision by the Heart team. The primary endpoints were 30-day and 2-year all-cause mortality. RESULTS: A total of 91 consecutive patients with mean age of 79 ± 9 years (52% men) underwent TAVI with a median follow-up duration of 16 months (interquartile range of 27.6 months). CAD was present on 46 patients (51%). At 30-day, the incidences of death were similar between CAD and non-CAD patients (9 and 5%, p = 0.44), but at 2 years were 50% in CAD patients and 24% in non-CAD patients [crude hazard ratio with CAD, 2.2; 95% confidence interval (CI), 1.1–4.6; p = 0.04]. Adjusting for age, gender, left ventricular ejection fraction, and glomerular filtration rate, the hazard of death was 2.6-fold higher in patients with CAD (95% CI, 1.1–6.0; p = 0.03). Elective PCI before TAVI was performed in 13 patients (28% of CAD patients). There were no more adverse events in patients who underwent TAVI + PCI when compared with those who underwent isolated TAVI. CONCLUSION: In severe symptomatic AS who underwent TAVI, CAD is frequent and adversely impacts long-term outcomes, but not procedure outcomes. In selected patients, PCI before TAVI appears to be feasible and safe. Frontiers Media S.A. 2015-04-15 /pmc/articles/PMC4671341/ /pubmed/26664890 http://dx.doi.org/10.3389/fcvm.2015.00018 Text en Copyright © 2015 Mancio, Fontes-Carvalho, Oliveira, Caeiro, Braga, Bettencourt and Ribeiro. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Mancio, Jennifer Fontes-Carvalho, Ricardo Oliveira, Marco Caeiro, Daniel Braga, Pedro Bettencourt, Nuno Ribeiro, Vasco Gama Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation |
title | Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation |
title_full | Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation |
title_fullStr | Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation |
title_full_unstemmed | Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation |
title_short | Coronary Artery Disease and Symptomatic Severe Aortic Valve Stenosis: Clinical Outcomes after Transcatheter Aortic Valve Implantation |
title_sort | coronary artery disease and symptomatic severe aortic valve stenosis: clinical outcomes after transcatheter aortic valve implantation |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671341/ https://www.ncbi.nlm.nih.gov/pubmed/26664890 http://dx.doi.org/10.3389/fcvm.2015.00018 |
work_keys_str_mv | AT manciojennifer coronaryarterydiseaseandsymptomaticsevereaorticvalvestenosisclinicaloutcomesaftertranscatheteraorticvalveimplantation AT fontescarvalhoricardo coronaryarterydiseaseandsymptomaticsevereaorticvalvestenosisclinicaloutcomesaftertranscatheteraorticvalveimplantation AT oliveiramarco coronaryarterydiseaseandsymptomaticsevereaorticvalvestenosisclinicaloutcomesaftertranscatheteraorticvalveimplantation AT caeirodaniel coronaryarterydiseaseandsymptomaticsevereaorticvalvestenosisclinicaloutcomesaftertranscatheteraorticvalveimplantation AT bragapedro coronaryarterydiseaseandsymptomaticsevereaorticvalvestenosisclinicaloutcomesaftertranscatheteraorticvalveimplantation AT bettencourtnuno coronaryarterydiseaseandsymptomaticsevereaorticvalvestenosisclinicaloutcomesaftertranscatheteraorticvalveimplantation AT ribeirovascogama coronaryarterydiseaseandsymptomaticsevereaorticvalvestenosisclinicaloutcomesaftertranscatheteraorticvalveimplantation |